Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

Alphabet subsidiary Verily is teaming up with well-known sleep company ResMed to form a new venture that will focus on developing sleep apnea treatments and connected health products. The latest ...

With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers. Patient monitoring companies within the healthcare ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

The “unlimited demand” for ResMed’s sleep apnea machines has given the San Diego, CA-based company the capital to become involved in some heavy-duty M&A. ResMed said it had signed a definitive ...

Loud snoring at night. Pauses in breathing followed by gasps for air while you’re asleep. Excessive daytime fatigue. Frequent nodding off in front of the TV or even when behind the wheel of a car.

With the pedal firmly to the metal in its U.S. business—thanks in no small part to rival CPAP machine maker Philips’ ongoing recall—ResMed has begun looking beyond its home turf to extend that winning ...

As it continues to take advantage of the gaping hole left in the CPAP machine market by competitor Philips’ ongoing respiratory recall troubles, ResMed is still fine-tuning its long-term growth ...

The Food and Drug Administration on Thursday classified the voluntary recall of certain respiratory masks made by ResMed as “most serious” as their incorrect use could cause major injuries or death.

ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS ...